Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511664 · ClinicalTrials.gov registry record · Phase 3
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Endocyte.
- Completed
- Registry status
- Phase 3
- Development phase
- 861
- Enrollment target
- 20
- Study locations
NCT03511664: Completed Phase 3 study of Prostate Cancer, sponsored by Endocyte.
NCT03511664 is a Phase 3 study of Prostate Cancer that has completed, run by Endocyte. The registered enrollment target is 861 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (42% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03511664, a Phase 3 study of Prostate Cancer, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 861 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.
Conditions Studied
Interventions
- DRUG 177Lu-PSMA-617
- OTHER Best supportive/best standard of care
Study Locations (20)
California
- VA Greater Los Angeles Healthcare System - Los Angeles
- University of California Los Angeles, Nuclear Medicine - Los Angeles
- Stanford Cancer Institute - Palo Alto
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Arizona
- HonorHealth Research Institute - Scottsdale
- University of Arizona Cancer Center - Tucson
Indiana
- Parkview Research Center - Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
- Iowa City VA Medical Center - Iowa City
Maryland
- University of Maryland Greenebaum Cancer Center - Baltimore
- Chesapeake Urology Associates (CUA) P.A. - Towson
Colorado
- University of Colorado Hospital - Aurora
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- Washington DC VA Medical Center, Nuclear Medicine Service - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 861 participants |
| Start Date | 2018-05-29 |
| Est. Completion | 2023-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03511664
The ClinicalTrials.gov registry entry for NCT03511664 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 861 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (42% higher). The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which 177Lu-PSMA-617 is the first listed.
NCT03511664 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Arizona, Indiana.
Frequently Asked Questions
What is clinical trial NCT03511664 about?
NCT03511664 is a clinical study titled "Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer". The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) wh...
What is the current status of trial NCT03511664?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 861 participants. The study started on 2018-05-29. Estimated completion is 2023-12-14.
What conditions does trial NCT03511664 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03511664?
The interventions under investigation include: 177Lu-PSMA-617 (DRUG), Best supportive/best standard of care (OTHER).
Who is sponsoring clinical trial NCT03511664?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03511664 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.